T. W. Geisbert

This paper shows a highly attenuated rVSV-based vaccine protects nonhuman primates against lethal Marburg virus challenge when administered up to 1 week before exposure.

This study examines the natural history of Ebola virus infection in nonhuman primates after conjunctival exposure, finding that lower doses result in delayed disease and reduced mortality.

A single-shot ChAd3-MARV vaccine provided rapid and durable protection against lethal Marburg virus infection in macaques, with antigen-specific antibodies correlating strongly with immunity.

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

This study identifies human monoclonal antibodies that neutralize HeV and NiV by targeting distinct antigenic sites on the receptor binding protein and demonstrates their cooperative binding and synergistic therapeutic effects.

This study shows that convalescent sera with high neutralizing antibody titers reduce SARS-CoV-2 viral load and disease severity in African green monkeys.

LY-CoV555, an anti-spike antibody from a convalescent COVID-19 patient, neutralizes SARS-CoV-2 and protects non-human primates against infection.

This study investigates the role of alpha-1-antitrypsin in inhibiting SARS-CoV-2 entry and shows variant-dependent effects on its ability to block different viral strains.

This study establishes an African green monkey model for COVID-19, showing high SARS-CoV-2 replication and severe respiratory disease with lower viral doses than in other NHP species.

This study investigates how Marburg and Ebola viruses elicit a complex, muted inflammatory response in bats, revealing mechanisms that may explain their non-pathogenicity in these animals.

This paper demonstrates that a two-antibody cocktail (MBP134AF) provides broad therapeutic protection against multiple ebolaviruses in ferrets and nonhuman primates.